Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Sunshine Biopharma ( (SBFM) ).
On May 18, 2026, Sunshine Biopharma Inc. entered into a placement agent agreement with Aegis Capital Corp. for a reasonable best‑efforts public offering of 12 million common or pre‑funded units, each including one share or pre‑funded warrant and two Series C warrants. The offering, which priced units at about $0.50 and closed on May 19, 2026, raised approximately $6 million in gross proceeds before fees, strengthening the company’s capital base for general corporate purposes and working capital while adding warrant‑linked leverage for investors.
Under the structure, pre‑funded warrants are immediately exercisable at a nominal price, and Series C warrants are exercisable at $0.50 for five years with anti‑dilution adjustments tied to potential share combination events, subject to Nasdaq stockholder approval requirements. Aegis Capital received a 7% placement fee and a 2% expense allowance, underscoring the cost of accessing public markets as Sunshine Biopharma seeks to support its expanding Canadian generics portfolio and ongoing proprietary drug development programs.
The most recent analyst rating on (SBFM) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Sunshine Biopharma stock, see the SBFM Stock Forecast page.
Spark’s Take on SBFM Stock
According to Spark, TipRanks’ AI Analyst, SBFM is a Neutral.
The score is held down primarily by persistent operating losses and consistently negative operating/free cash flow, despite some revenue scale and low leverage. Technicals further weaken the outlook with a pronounced downtrend (below all major moving averages and negative MACD), while valuation offers limited support due to negative earnings and no dividend yield provided.
To see Spark’s full report on SBFM stock, click here.
More about Sunshine Biopharma
Sunshine Biopharma Inc. is a pharmaceutical company focused on life‑saving medicines in oncology, antivirals, and other key therapeutic areas. The company currently markets 60 generic prescription drugs in Canada, plans 12 additional launches in 2026, and is advancing proprietary programs including an mRNA‑LNP liver cancer candidate and a PLpro protease inhibitor for SARS‑related coronavirus infections.
Average Trading Volume: 7,265,863
Technical Sentiment Signal: Strong Sell
Current Market Cap: $1.42M
Find detailed analytics on SBFM stock on TipRanks’ Stock Analysis page.